TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market– Drivers and Restraints

• Increasing diagnosis of ATTR-CM: Due to advancements in echocardiography and cardiac MRI techniques, doctors can more accurately diagnose ATTR-CM. Earlier, ATTR-CM was difficult to differentiate from other cardiomyopathies based on symptoms alone. However, new technologies like nuclear scintigraphy imaging using radioisotope tracers that target misfolded amyloid proteins in the heart have drastically improved diagnosis rates. In April 2023, according to an article published by StatPearls, a professional healthcare education and technology company, non-invasive cardiac imaging like cardiac MRI and bone avid scintigraphy contribute significantly in diagnosis of ATTR-CM.  Doctors are also learning to recognize vague but characteristic echocardiogram findings which help in diagnosis of ATTR-CM. The improved understanding of the disease manifestations, combined with better diagnostic tools have allowed identification of many cases that were previously overlooked or misdiagnosed. As more patients receive an accurate ATTR-CM diagnosis, the eligible patient pool for disease modifying therapies will naturally expand in the near future.
• Growing elderly population: Growing elderly population demographic is major driver of the market as more patients will need therapy over time. In January 2023, according to the World Social Report 2023 published by United Nations, the number of people aged 65 and older globally is expected to be more than double from 2021 to 2050. The number of people aged 65 years or above is estimated increase from 761 Mn in 2021 to 1.6 Bn in 2050. Moreover, the oldest old population (persons aged 80 years or over) is the fastest growing segment of the world’s population. ATTR-CM primarily affects the elderly, and its prevalence increases significantly with age. The rare form caused by mutations early-onset whereas the more common wild-type ATTR-CM usually occurs after age 65 years. With substantial growth in the numbers of aging population globally, the pool of individuals at high risk of developing age-related amyloidosis and ATTR-CM will expand rapidly, and thus, creating an upward pressure on disease incidence rates in the near future.

Restraints

• Lack of awareness of ATTR-CM: Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market faces several restraints. Firstly, lack of awareness and understanding of ATTR-CM among healthcare professionals often leads to misdiagnosis or delayed diagnosis, which is expected to hamper the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth. Secondly, the high cost of treatment becomes a hindrance for many patients, which is expected to hamper the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth. Thirdly, the side effects associated with some treatments can deter patients from continuing with their medication regimen. The limited number of approved drugs for ATTR-CM treatment restricts the options available for patients and physicians. Lastly, the complexity of the disease, which often co-exists with other conditions like heart failure, makes management and treatment more challenging. These factors combinedly contributes to the restraint of the ATTR-CM treatment market.
• Counterbalance: Manufacturers should focus on increasing awareness about ATTR-CM among both healthcare providers and general population by organizing disease awareness programs among the masses.